Trials / Recruiting
RecruitingNCT06926491
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）
A Multicenter, Open-label, Single-arm, Phase 3 Study of KK8398 (Infigratinib) in Patients With Achondroplasia (AOBA Study)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will evaluate the efficacy of KK8398 on annualized height velocity after 52 weeks of repeated administration of KK8398 to patients with achondroplasia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KK8398 | KK8398 will be administered. |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2029-05-31
- Completion
- 2031-05-31
- First posted
- 2025-04-13
- Last updated
- 2025-04-29
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06926491. Inclusion in this directory is not an endorsement.